consensus has been reached about the exact origin of myofibroblasts during TIF, but activated resident fibroblasts are generally regarded as an important source of interstitial myofibroblasts (15) . However, the mechanism of resident fibroblast activation is poorly understood.
MAD2B (also referred to as MAD2L2 and hRev7), a protein of 211 amino acids, has emerged as an important regulator of the cell cycle (21) by acting as an APC/C inhibitor (1) . In the pro-metaphase, MAD2B sequesters free CDH1 away from the anaphase-promoting complex/cyclosome (APC/C) and keeps APC/C inactive, while, once entering into anaphase, MAD2B is rapidly degraded by APC/C CDC20 , accompanied by CDH1 release, which ultimately results in APC/C activation and cell cycle arrest (12) . Moreover, as a subunit of DNA polymerase , MAD2B is also involved in replicating damaged DNA and regulating DNA repair activity (21) . Therefore, MAD2B plays a crucial role in proper mitotic progression and faithful DNA replication. Accumulating evidence indicated that MAD2B is overexpressed in tumor genesis and tightly correlated with the progression and prognosis of these malignancies, such as colon cancer, epithelial ovarian cancer, and glioma (2, 19, 20, 31) . Previously, we reported that hyperglycemia mediates neuronal apoptosis through inducing the production of MAD2B, which represents a novel mechanism of diabetic encephalopathy (17) .
In the kidney, we proved MAD2B is presented in glomeruli and the tubulointerstitum. Also, MAD2B is upregulated in the renal cortex of diabetic nephropathy (DN) patients and mice. Additionally, MAD2B aggravates podocyte impairment via modulating the APC/C-cyclin pathway. Meanwhile, knocking down MAD2B ameliorates high glucose-induced podocyte injury, which indicates that MAD2B plays a pivotal role in podocyte injury during DN (25) . However, the role of MAD2B in the development and progression of TIF, especially in fibroblast activation, has not been clarified.
Transforming growth factor-␤1 (TGF-␤1) is a well-recognized profibrotic molecule, and SnoN is one of the negative regulators of TGF-␤1 signaling. It is known that SnoN can be ubiquitinated and degraded by the APC/C E3 ubiquitin ligase (4) . As an APC/C repressor, whether MAD2B participates in fibrotic processes by governing SnoN expression is unclear. Here, we investigate the potential roles of MAD2B and its interplay with SnoN during TIF and fibroblast activation.
In the current study, we present new findings that MAD2B is involved in the activation of fibroblasts and the progression of TIF. Moreover, MAD2B downregulates SnoN, a repressor of TGF-␤1 signaling, in an APC/C-independent and ubiquitination-dependent manner and is one of the underlying mechanisms accounting for MAD2B's profibrotic property. Animal samples. Age-matched (12 wk) adult C57BL/6 mice were purchased from the animal center at Wuhan University. The unilateral ureteral obstruction (UUO) procedure was performed as previously described (6) . Mice in the UUO group were euthanized at days 1, 3, and 7, respectively, after the operation. Sham-operated mice were euthanized at day 7 after surgery. The animals were perfused in the heart with heparinized saline solution before death.
Intrarenal lentivirus delivery. Recombinant lentivirus vectors harboring a short-hairpin (sh) RNA sequence targeting MAD2B (shRNA-MAD2B) were produced by JikaiGene (Shanghai, China). Two days before UUO model establishment, shRNA-MAD2B or their negative controls (scrambled) were delivered into the mice kidney by means of intraparenchymal injections. The procedure for intraparenchymal lentivirus delivery was performed as described before (9, 11) . Briefly, after anesthesia the renal pedicle of the mice was temporarily occluded, and then a 31-G needle was inserted from the lower pole of the kidney parallel to the long axis and was carefully pushed toward the upper pole. As the needle was slowly moved backward, 100 l of scrambled or MAD2B lentivirus shRNA (ϳ1 ϫ 10 5 IU/l) was injected. Studies by us and other groups indicated that green fluorescent protein (GFP), the indicator of lentiviral transfection, was significantly increased in kidney parenchyma at 48 h after injection, and no toxicity was observed in mice treated with the lentiviral vector (9, 11) . Cell culture, treatment, and transfection. Rat renal fibroblasts (NRK-49F) were obtained from the American Type Culture Collection (ATCC). NRK-49F cells were cultured in DMEM containing 4,500 mg/l glucose, supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, and 10% fetal bovine serum at 37°C in the presence of 5% CO 2. Once reaching 70 -80% confluence, NRK-49F cells were serum starved for 12 h and then subjected to human TGF-␤1 exposure (5 ng/ml, R&D Systems, Minneapolis, MN) for the indicated times before collection.
MAD2B shRNA and CDH1 small interfering (si) RNA were obtained from JikaiGene (Shanghai, China) and Ribobio (Guangzhou, China) to silence MAD2B and CDH1 gene expression in NRK-49F cells, respectively. The scrambled shRNA (JikaiGene) or scrambled siRNA (Ribobio) was used as a control. After synchronized for 12 h, NRK-49F cells were transfected with shRNA or siRNA according to the manufacturer's instruction. Forty-eight hours after transfection, TGF-␤1 (5 ng/ml) was mixed into the medium for the corresponding time to conduct the following experiments.
Histopathological and immunohistochemical analyses. Kidney tissues were fixed by 4% paraformaldehyde in PBS and embedded in paraffin. Tissue sections (3 m thick) were stained with Masson's trichrome for histopathological analysis. Immunoreactivity for MAD2B and SnoN proteins was determined by using a standard biotin-streptavidin-peroxidase method as described previously (25) . The primary antibodies were rabbit anti-MAD2B antibody (1:100; Abcam, Cambridge, MA) and rabbit anti-SnoN (1:200; Santa Cruz Biotechnology, Santa Cruz, CA). The secondary antibody was affinity-purified biotinylated goat anti-rabbit immunoglobulin G (Cortex Biochem, San Leandro, CA). The negative control was performed by replacing the primary antibodies with PBS. Nuclei were counterstained lightly with hematoxylin. The randomly chosen renal interstitial areas were analyzed by using Image-Pro Plus 6.0 software (Media Cybernetics, Rockville, MD), and integrated optical density was used to evaluate relative amount of positive staining.
Immunofluorescence staining. Indirect immunofluorescence staining was performed using an established procedure (7) . Briefly, kidney cryosections were prepared and mounted onto poly L-lysine-coated slides and fixed in 4% paraformaldehyde in PBS for 30 min, then permeabilized with 0.3% Triton X-100 in PBS for 15 min, and blocked with 5% donkey serum for 30 min at 37°C. Thereafter, the slides were incubated with rabbit anti-MAD2B antibody (1:100; Abcam) overnight at 4°C. After PBS washing, the slides were incubated with Alexa 488-labeled secondary antibodies at room temperature for 1 h. The negative control was performed by replacing the primary antibodies with PBS. The images were captured by confocal microscopy at identical microscopic settings and analyzed by using Image-Pro Plus 6.0 software (Media Cybernetics). The integrated optical density was used to evaluate relative amount of positive staining.
Western blot analysis. Immunoblotting was performed as previously described (30) . In short, proteins from mouse cortex or cultured cells were extracted with RIPA lysis buffer (Beyotime, Jiangsu, China). BCA Protein Assay kit (Bio-Rad, Hercules, CA). After boiling for 5 min at 95°C in 5ϫ loading buffer, an equal amount of protein (40 g) was loaded onto an SDS-polyacrylamide gel for electrophoresis and then transferred to polyvinylidene difluoride membranes (Merck Millipore, Billerica, MA). After blocking with 5% BSA for 1 h, the membranes were incubated overnight at 4°C with the following primary antibodies: rabbit anti-MAD2B antibody (1:1,000; Abcam), rabbit anti-p-Smad3 (1:1,000; Santa Cruz Biotechnology), rabbit antiSnoN antibody (1:500; Protein Tech Group, Chicago, IL), rabbit anti-CDH1 antibody (1:1,000; Abcam), rabbit anti-collagenⅢ antibody (1:1,000; Protein Tech Group), rabbit anti-␣-smooth muscle actin (SMA) antibody (1:1,000; Protein Tech Group), and mouse anti-␤-actin antibody (1:10,000; Santa Cruz Biotechnology). ␤-Actin was used as an internal control. After incubation with appropriate secondary antibodies, the immunoreactive bands were detected by chemiluminescence methods and visualized on Kodak Omat X-ray films. Densitometric analysis of the images obtained from X-ray films was performed by using Image J software (NIH, Bethesda, MD).
RNA extraction and quantitative RT-PCR.
Total RNA was extracted from the cells by TRIzol reagent (Invitrogen, Shanghai, China) according to the manufacturer's protocol. The mRNA levels of target genes were analyzed by real-time quantitative RT-PCR as described previously (17) . In short, aliquots of total RNA (1 g) from each sample were reverse-transcribed into cDNA according to the manusfacturer's instructions (Bio-Rad). Then, equal amounts of the reverse transcriptional products were subjected to quantitative PCR by using SYBR Green dye (Applied Biosystems, Shanghai, China) and Applied Biosystems hardware and software (7500 RT-PCR System). The mRNA levels of target genes were normalized to the corresponding GAPDH mRNA levels. The 2
ϪCt method was used to calculate relative expression of the targeted genes. The primers used in this study were synthesized by Sangon Biotech (Shanghai, China), and the sequences were as follows: SnoN, forward 5=-GTGTCTGGAGT-GCTGTGGAA-3= and reverse 5=-GCTGGGGTGTAAAAATGA-ATG-3=; MAD2B, forward 5=-TGG ACATCTTGCTCATCTGC-3= and reverse 5=-TGCTTCGAGCCTTCATTCTT-3=; and GAPDH, forward 5=-ATGGTGGTGAAGACGCCAGTA-3= and reverse 5=-GGC ACAGTCAAGGCTGAGAATG -3=.
Statistical analyses. All of the values are expressed as means Ϯ SE. Significant differences between two groups were examined by using a paired t-test. P Ͻ 0.05 was considered as statistically significant. 
RESULTS

Expression of MAD2B is enhanced in tubulointerstitial area of TIF patients and UUO mice.
To explore the relevance of MAD2B and renal fibrosis, we investigated MAD2B protein expression in kidney biopsies from patients with primary glomerular diseases. The degree of TIF was evaluated by Masson staining and divided into mild, moderate, and severe groups. By immunofluorescence staining, we found that in humans, besides glomeruli, MAD2B is also expressed in the renal tubulointerstitial compartment. The intensity of tubulointerstitial MAD2B is positively related to the severity of TIF, and in severe TIF patients the levels of MAD2B is much higher than that in mild TIF groups (P Ͻ 0.05) (Fig. 1, A and B) .
In UUO and sham-operated (control) mice, the kidney on the operated side was removed at 1, 3, or 7 days after surgery. By immunohistochemistry, significant nuclear and cytoplasmic staining in tubulointerstitial regions in mice was shown, the same staining pattern as in humans. Compared with the control group, MAD2B abundance in UUO mice was increased markedly in a time-dependent manner, which started to rise at 3 days after surgery and reachd the peak on day 7. This finding was further verified by Western blotting (Fig. 1, C-F) .
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Upregulated MAD2B is implicated in TGF-␤1-induced fibroblast activation. Currently, accumulating data support that resident fibroblasts are the dominant source of collagen-producing myofibroblasts (5, 8) . Thus we next assessed the role of MAD2B in TGF-␤1-stimulated fibroblasts. Fibroblasts (NRK-49F cells) were incubated with 5 ng/ml TGF-␤1 for the indicated times and collected for subsequent analysis. As we can see in Fig. 2, A and B , in response to TGF-␤1 MAD2B levels are elevated at 12 h of stimulus, accompanied by activation of myofibroblasts, which was proved by upregulated ␣-SMA (indicator of fibroblast transdifferentiation) and collagen Ⅲ (indicator of ECM accumulation). Furthermore, depression of MAD2B by lentivirus shRNA can largely abrogate the TGF-␤1-induced fibroblast activation, which infers that MAD2B is actively engaged in fibroblast activation triggered by TGF-␤1 (Fig. 2, C and D) .
Local genetic deletion of MAD2B in the kidney cortex alleviates TIF in UUO mice. To take advantage of the local lentivirus transfection technique, MAD2B in the renal cortex was regionally suppressed before the surgery. Our data showed after lentivirus delivery that the MAD2B level is reduced by ϳ40 -50%. The most exciting results are that local genetic deletion of MAD2B can dramatically attenuate fibroblast activation in UUO mice, manifesting as decreased ␣-SMA (Fig. 3, A-D) . Furthermore, local suppression of MAD2B also minimizes fibronectin (FN) abundance and ECM deposition, which was proved by immunostaining and Masson trichrome staining (Fig. 4, A-D) .
SnoN, a negative regulator of TGF-␤1, is reduced in TIF patients and UUO mice, which can be prevented by local MAD2B knockdown. Next, we explored the potential mechanisms accounting for MAD2B-associated TIF. As we know, SnoN, a welldefined TGF-␤1/Smad transcriptional repressor, can be ubiquitinated by APC/C; thus we were intensely curious about whether MAD2B, an APC/C inhibitor, could interfere with TGF-␤1-SnoN signaling. By immunohistochemistry, it was shown that SnoN is expressed in the renal tubulointerstitial compartment and its level is reduced in TIF patients and UUO mice (Fig. 5, A-D) . Consistently, Western blotting indicates immunoreactivity of SnoN is markedly attenuated in UUO mice (Fig. 5, E and F) .
Thereupon, we observed the link between MAD2B and SnoN via local lentivirus transfection to suppress MAD2B in the cortex before the unilateral ureteral ligation. After lentivirus injection, the MAD2B level is reduced by ϳ40 -50%. Furthermore, genetic deletion of MAD2B can obviously prevent SnoN reduction as well as Smad3 phosphorylation (Fig. 6, A and B) .
MAD2B genetic deletion attenuates the decline of SnoN protein in fibroblasts exposed to TGF-␤1. In in vitro cultured fibroblasts, we first evaluated the mRNA transcription level of SnoN and found it is not affected by TGF-␤1 stimulation (Fig. 7A) . However, Fig. 7 , B and C, shows that the SnoN protein level is reduced in fibroblasts after exposure to 5 ng/ml TGF-␤1 from 1 h and sustained to 6 h, along with enhanced Smad3 phosphorylation. Knocking down MAD2B by lentivirus shRNA significantly attenuates SnoN protein reduction and Smad3 activation (Fig. 7, D  and E) . The results above are in line with our in vivo study.
The reduction of SnoN protein is not associated with APC/ C CDH1 ubiquitin ligase but related to other ubiquitin enzyme systems in fibroblasts exposed to TGF-␤1. As we know, MAD2B is a negative regulator of the activity of APC/C CDH1 E3 ubiquitin ligase; thus the downregulation of SnoN cannot be explained by the MAD2B-APC/C CDH1 pathway during TGF-␤1-initiated fibroblast activation. Also, CDH1 siRNA transfection could not reverse TGF-␤1-indcued SnoN degradation in NRK-49F cells exposed to 5 ng/ml TGF-␤1 for 24 h (Fig. 8, A  and B) . Intriguingly, using an ubiquitin-activating enzyme (E1) inhibitor, PYR-41 (10 M, pretreated for 30 min), to block posttranscriptional ubiquitination preserves SnoN abundance during TGF-␤1 exposure (Fig. 8, C and D) .
DISCUSSION
Since first identified in 1999, MAD2B is primarily considered to participate in APC/C-related mitosis control and DNA repair (3, 12, 16, 18, 28) . Besides cell cycle regulation and error-free DNA maintenance, other functions of MAD2B are rarely known. In our earlier study, we demonstrated that MAD2B is extensively expressed in human and mouse kidneys as well as several renal cell lines. Additionally, we proved that MAD2B is implicated in podocyte injury under diabetic status (25) . Currently, our data reveal that MAD2B expression is upregulated in the renal tubulointerstitial area of patients with primary glomerular diseases, and the level of MAD2B protein is positively correlated to TIF severity. Consistently, in UUO mice, one of the generally accepted renal fibrosis animal models, the abundance of MAD2B in the kidney cortex is elevated from 3 days after surgery and continues to rise at day 7, and this enhancement is mainly taking place in tubulointerstitial areas. This finding suggests that MAD2B may have potential roles in TIF.
Although the origin of collagen-producing myofibroblasts is still in dispute, recent lineage tracing and fate determination studies propose that myofibroblasts derived from resident fibroblasts contribute importantly to ECM accumulation and TIF progression (14, 15) . Thus we examined MAD2B expression in cultured fibroblasts and found that with TGF-␤1 stimulation fibroblast MAD2B is dramatically upregulated in a time-dependent manner, which is accompanied by fibroblast activation, marked by ␣-SMA and collagen III accumulation. In addition, ␣-SMA and collagen III induction upon TGF-␤1 exposure can be largely abrogated by MAD2B genetic deletion, which reveals a novel profibrotic role for MAD2B. Consistent with these in vitro results, we found that local knockdown of MAD2B in the kidney significantly alleviated TIF in UUO mice. Collectively, these data support the idea that MAD2B plays an essentially pathogenic role in fibroblast activation and subsequent TIF progression. Next, we explored the underlying mechanisms involved in MAD2B-related fibrosis. SnoN, one of the negative regulators of TGF-␤1 signaling, binds with the p-Smad2/3 complex and disrupts its interaction with Co-Smad4 and nuclear translocation, thereby preventing target gene transcription. Beyond that, SnoN recuits transcriptional corepressors, such as histone deacetylases (HDACs), to the promoter of TGF-␤1-regulated genes or prevents the binding of coactivators to further dampen TGF-␤1 signaling (10, 29) . Accordingly, SnoN acts as a safeguard in health kidneys and prevents an excessive TGF-␤1 response (29), so the aberrant SnoN level will lead to an inappropriate cell response after TGF-␤1 stimulation.
In the present study, it was found that SnoN protein but not its mRNA level is decreased upon TGF-␤1 stimulation in cultured fibroblasts. In addition, the expression of SnoN protein in TIF patients and the UUO model is also suppressed, which is associated with the degree of TIF. In line with our findings, there are several other studies illustrating a rapid and significant decline of SnoN levels in obstructed kidneys, which is regarded as an amplification mechanism for TGF-␤1 signaling (29) . Further studies by our and other laboratories show this downregulation is mainly due to enhanced ubiquitin-dependent degradation but not altered gene transcription or mRNA stability (26) .
Several E3 ubiquitin ligases are reported to be responsible for SnoN degradation in response to TGF-␤1, among which Smad-induced Smurf2 E3 ligase activation is most essential for SnoN ubiquitination and degradation (22, 23) . However, Smads also stimulate the gene transcription of SnoN (24) . APC/C is another key E3 ligase accounting for SnoN ubiquitination. Since MAD2B governs the switch between APC/ C CDC20 and APC/C CDH1 (12) and regulates the ubiquitination activity of APC/C, it is reasonable to speculate that MAD2B may play its profibrotic role via regulating the ubiquitin ligase activity of APC/C and consequently mediating SnoN degradation. Intriguingly, our results reveal that the decline of SnoN protein in TGF-␤1-treated fibroblasts and UUO mice can be obviously alleviated by MAD2B knockdown, which is accompanied by diminished myofibroblast activation and ECM accumulation. The aforementioned data propose SnoN is negatively modulated by MAD2B, which may be one of the underlying mechanisms accounting for the following Smad activation and renal fibrosis.
It is reported that SnoN is ubiquitinated by APC/C CDH1 and then degraded in axon and hematological lineage cells (22, 27) . Nevertheless, it seems not to be true during renal fibroblast activation since the increment of APC/C CDH1 inhibitor MAD2B promotes SnoN degradation conversely. regulation of SnoN is not via APC/C. However, blocking posttranscriptional ubiquitination can significantly preserve SnoN content, which indicates other ubiquitin enzyme systems may be involved in TGF-␤1-induced SnoN degradation. Further investigation is needed to address this issue.
In summary, this is the first report concerning the pathogenic role of MAD2B in fibroblast activation and TIF progression. Here, we provide the evidence that tubulointerstitial MAD2B is upregulated, accompanied by reduced SnoN levels in TIF patients and obstructed mouse kidneys as well as the cultured fibroblasts exposed to TGF-␤1. Genetic suppression of MAD2B can preserve the abundance of SnoN and eventually dampen fibroblast activation and ECM accumulation both in vivo and in vitro. Taken together, besides acting as a governor of cell cycle and DNA repair, MAD2B possesses a profibrotic character by depressing SnoN, a negative modulator of TGF-␤1 signaling. In addition, MAD2B might be a promising therapeutic target for TIF.
